R&D for an Integrated Sweetener Supplier Platform

「In October 2024, the company entered into an advisory agreement with Metagen Co., Ltd., a leader in cutting-edge gut-environment research, and is advancing initiatives to promote basic research and the practical application of research results in society.」

「CI's R&D is producing results that have been recognized both in Japan and overseas, including jointly receiving the Japan Society for Applied Glycoscience's Technology Development Award with the University of Yamanashi in September 2024, and a research report announced by the company in May 2024 receiving the Sugar Technology Research Association Award.」

「In Itochu Sugar Co., Ltd., a joint research department for medical pre- and probiotics was established at Fujita Health University in August 2022. The research focuses on Kestose, a prebiotic material owned by the company, with the aim of maintaining human health and providing complementary treatment for disease. Sales of Kestose began in October 2021. The company is also advancing cooperation in R&D with Tsuruyakasei Co., Ltd., which became an equity-method affiliate in May 2023. Total group-wide R&D expenses for the fiscal year were ¥209 million.」

「On 1 June 2023, we established the Functional Materials Department, an organization for functional materials reporting directly to the president, and are promoting R&D and making active investments by bringing together the expertise and resources held by 日新製糖㈱ and 伊藤忠製糖㈱. The group's total R&D expenses for the cumulative third quarter were ¥168 million.」

「On 1 June 2023, we established the Functional Materials Department, an organization for functional materials reporting directly to the president, and are promoting R&D and making active investments by bringing together the expertise and resources held by 日新製糖㈱ and 伊藤忠製糖㈱. The group's total R&D expenses for the cumulative second quarter were ¥113 million.」

「On 1 June 2023, we established the Functional Materials Department, an organization for functional materials reporting directly to the president, and are promoting R&D and making active investments by bringing together the expertise and resources held by 日新製糖㈱ and 伊藤忠製糖㈱.」

「In connection with this business integration, we are bringing together the R&D expertise and resources held by both companies and working to establish a framework for providing a diverse range of functional materials and realizing “Well-being” (happiness and health).」

「The group's total R&D expenses for the cumulative second quarter were ¥60 million. There were no material changes in the status of the group's R&D activities during the cumulative second quarter.」

「The group's total R&D expenses for the cumulative first quarter were ¥31 million. There were no material changes in the status of the group's R&D activities during the cumulative first quarter.」

「The group's total R&D expenses for the cumulative second quarter were ¥63 million. There were no material changes in the status of the group's R&D activities during the cumulative second quarter.」

「The group's total R&D expenses for the cumulative first quarter were ¥32 million. There were no material changes in the status of the group's R&D activities during the cumulative first quarter.」

「As part of our comprehensive sweetener supplier strategy, we are advancing the development of new products using sugar and other sweeteners and research into new functions of galacto-oligosaccharides. At the Okinawa Lab, we are conducting R&D on the functional carbohydrate cyclodextrin (CI), which is expected to be useful in oral-care materials and in solubilizing poorly soluble substances, and began manufacturing and sales in May 2021. To advance this R&D, we are actively deepening collaboration with universities and other research institutions through joint research to enhance expertise and efficiency. Total group R&D expenses for the fiscal year were ¥124 million, all of which related to the sugar and other food products business.」

「The group's total R&D expenses for the cumulative third quarter were ¥96 million. There were no material changes in the status of the group's R&D activities during the cumulative third quarter.」

「The group's total R&D expenses for the cumulative second quarter were ¥63 million. There were no material changes in the status of the group's R&D activities during the cumulative second quarter.」

「The group's total R&D expenses for the cumulative first quarter were ¥26 million. There were no material changes in the status of the group's R&D activities during the cumulative first quarter.」

「To advance this R&D, we are actively deepening collaboration with universities and other research institutions to enhance expertise and efficiency. Total group R&D expenses for the fiscal year were ¥133 million, all of which related to the sugar and other food products business.」

「The group's total R&D expenses for the cumulative third quarter were ¥94 million. There were no material changes in the status of the group's R&D activities during the cumulative third quarter.」

「The group's total R&D expenses for the cumulative second quarter were ¥61 million. There were no material changes in the status of the group's R&D activities during the cumulative second quarter.」

「The group's total R&D expenses for the cumulative first quarter were ¥28 million. There were no material changes in the status of the group's R&D activities during the cumulative first quarter.」

「As part of our comprehensive sweetener supplier strategy, we are developing new products using sugar and other sweeteners and conducting functional research on galacto-oligosaccharides. As part of expanding our business scope, we are also pursuing R&D focused on applications in non-food fields, including functional carbohydrates expected to help prevent dental caries and solubilize poorly soluble substances, and cosmetic ingredients capable of providing cell-protective effects. At ツキオカフィルム製薬株式会社, R&D is being advanced in three areas that leverage the diverse properties of films: edible films, film cosmetics and film formulations.」

「The group's total R&D expenses for the cumulative third quarter were ¥56 million. There were no material changes in the status of the group's R&D activities during the cumulative third quarter.」

「The group's total R&D expenses for the cumulative first quarter were ¥20 million. There were no material changes in the status of the group's R&D activities during the cumulative first quarter.」

「To strengthen our foundation as a comprehensive sweetener supplier, our Business Development Department (sugar and other food products business) is conducting research into sugar, sweeteners and other new materials, planning and developing new products, and surveys and research to improve existing products and production efficiency. Total R&D expenses for the fiscal year were ¥72 million.」

「The group's total R&D expenses for the cumulative third quarter were ¥52 million. There were no material changes in the status of the group's R&D activities during the cumulative third quarter.」

「The group's total R&D expenses for the cumulative first quarter were ¥15 million. There were no material changes in the status of the group's R&D activities during the cumulative first quarter.」

「To strengthen our foundation as a comprehensive sweetener supplier, our Business Development Department (sugar and other food products business) is conducting planning, development and research into new sugar and sweetener products, as well as surveys and research to improve existing products and production efficiency. Total R&D expenses for the fiscal year were ¥73 million.」